icon
icon
icon
icon
🏷️$300 Off
🏷️$300 Off

News /

Articles /

Pfizer Stock Drops 2.84% Amid Earnings Concerns

Mover TrackerWednesday, Apr 9, 2025 6:45 am ET
1min read

On April 9, 2025, Pfizer's stock experienced a 2.84% drop in pre-market trading, reflecting a challenging period for the pharmaceutical giant.

Analysts from UBS have lowered their earnings per share (EPS) forecast for Pfizer's first quarter to $0.67, below the consensus estimate of $0.71. This revision is primarily due to concerns over the underperformance of Pfizer's COVID-19 related products, including the Paxlovid treatment and the Comirnaty vaccine, which are expected to fall short of market expectations in the first quarter.

Pfizer's current market value stands at $125 billion, a significant decline from its peak during the COVID-19 pandemic. The company is grappling with multiple challenges, including a substantial debt burden and a product pipeline that is under scrutiny. The absence of a stock buyback program in 2024 and no plans for one in 2025 further adds to investor concerns, as the company focuses on reducing debt from recent acquisitions.

Investors are eagerly awaiting more data on Pfizer's GLP-1 weight loss drug, danuglipron, which is currently in clinical trials. This oral medication has the potential to compete with existing GLP-1 drugs that are only available in injectable form. Success in this area could provide a much-needed boost to Pfizer's revenue, especially as sales of its COVID-19 related products continue to decline.

Despite these challenges, Pfizer remains committed to maintaining and increasing its dividend, which currently stands at 7.9%, one of the highest in the S&P 500. The company's chief financial officer, David Denton, has reassured investors of their commitment to achieving a deleveraged balance sheet by the end of 2025, which would provide a more balanced capital allocation strategy.

Comments

Add a public comment...
Post
User avatar and name identifying the post author
_Ukey_
04/09
$VKTX doesn't matter, you're just echoing the shorts. Tariffs barely affect Pfizer, and they have $20B in cash; nobody said they can't borrow. VIKing's CEO told investors that the Roche deal wasn't great, so he's not rushing into anything like most of us here. The pressure's more on Pfizer.
0
Reply
User avatar and name identifying the post author
InevitableSwan7
04/09
$PFE Hey everyone I own PFE and have been taking the drug for 3 years :)
0
Reply
User avatar and name identifying the post author
auradragon1
04/09
$PFE The BIGGEST US Pharma with the BIGGEST US factories. 8% Dividend. :)
0
Reply
User avatar and name identifying the post author
Phuffu
04/09
$PFE every day the market is up we have some dumb reason to be down
0
Reply
User avatar and name identifying the post author
Keroro999
04/09
$PFE looks like it's at a 5 year low 🤔 decent dividend too... where is pfe on the tariffs
0
Reply
User avatar and name identifying the post author
livinginahologram
04/09
@Keroro999 How long you been holding $PFE? Curious if you're thinking short-term flip or long-term dividend play.
0
Reply
User avatar and name identifying the post author
TheLastMemeLeft
04/09
$NVAX Heading down with Pfizer?
0
Reply
User avatar and name identifying the post author
pd14200
04/09
$PFE PE is just 6... are they going to ruin this company
0
Reply
User avatar and name identifying the post author
Booknerdworm
04/09
@pd14200 Low PE can be risky, but Pfizer's got potential with danuglipron.
0
Reply
User avatar and name identifying the post author
neurologique
04/09
$PFE if they kept quiet about bad Danuglipron news for the past week instead of releasing it earlier when it wouldn't have made a difference...the entire board should be fired
0
Reply
User avatar and name identifying the post author
that_is_curious
04/09
$PFE keeps going down, sell it like a penny stock
0
Reply
User avatar and name identifying the post author
jeditataween
04/09
Pfizer's COVID vaccine is fading, but their new weight loss drug might be the cure for their sinking stock
0
Reply
User avatar and name identifying the post author
alvisanovari
04/09
@jeditataween What if danuglipron flops?
0
Reply
User avatar and name identifying the post author
Zhukov-74
04/09
@jeditataween Agreed, weight loss drug could help.
0
Reply
User avatar and name identifying the post author
rbrar33
04/09
Holy!PFE demonstrated textbook-perfect bottom and peak confirmation signals via Peak Seeker framework,with subsequent price movements validating 83.6% predictive accuracy
0
Reply
User avatar and name identifying the post author
RubiksPoint
04/09
@rbrar33 What's your take on PFE's pipeline?
0
Reply
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
You Can Understand News Better with AI.
Whats the News impact on stock market?
Its impact is
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App